Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07240753Not Yet Recruiting

A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma

Role: collaborator

NCT05823311Phase 3Recruiting

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Role: collaborator

NCT03955367Phase 3Unknown

Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer

Role: collaborator

All 3 trials loaded